Samuel Z. Goldhaber, MD is the section head for Vascular Medicine and director of the Thrombosis Research Group within the Cardiovascular Medicine Division of Brigham and Women’s Hospital (BWH). He is a professor of medicine at Harvard Medical School (HMS).
He received his medical degree from HMS. He completed his internal medicine residency at Peter Bent Brigham Hospital (now BWH) and was appointed as chief medical resident at the Veterans Administration Medical Center in West Roxbury (now VA Boston Healthcare System). He then completed his cardiology fellowship at Peter Bent Brigham Hospital (now BWH). Dr. Goldhaber is board certified in cardiovascular disease and internal medicine.
Dr. Goldhaber’s clinical interests include general cardiology as well as novel oral anticoagulants, stroke prevention in atrial fibrillation, reduction of inflammation to prevent myocardial infarction, and the epidemiology, management, and prevention of pulmonary embolism (PE) and deep vein thrombosis (DVT). He directs several Continuing Medical Education courses for BWH and HMS, including a 5-day update in cardiology for the practitioner and a 2-day course on Thrombosis and Thromboembolism. Dr. Goldhaber is committed to community outreach. He helped found the North American Thrombosis Forum (www.NATFonline.org), a nonprofit organization which educates healthcare practitioners and patients, and he serves as NATF’s president.
His extensive research and publications focus on PE, DVT, and stroke prevention in atrial fibrillation. He chairs the steering committee of the ATTRACT Trial, which is studying the optimal method to manage massive DVT. He is principal investigator of clinical and observational trials of PE and DVT prevention and treatment as well as of stroke prevention in atrial fibrillation. His research has received funding from the National Institutes of Health.
